Skip to Main Content

Last July, Biogen (BIIB) executives unveiled a new, more aggressive business development plan. Cash thrown off by the biotech’s maturing but still very profitable multiple sclerosis franchise would be redeployed to license or acquire new neuroscience assets.

Biogen was eyeing prospective deals up to $10 billion to $12 billion in size, CEO Michel Vounatsos told investors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!